Table 4. PSA-PFS and OS for IDC-P-positive mCRPC patients.
| PSA-PFS | Univariate analysis | Model without therapeutic scheme | Model with therapeutic scheme | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| CFS (mo), ≥ 10 vs. < 10 | 0.55 (0.26–1.17) | 0.119 | 0.72 (0.32–1.62) | 0.432 | 0.52 (0.21–1.25) | 0.144 |
| Gleason score, ≥ 8 vs. < 8 | 1.72 (0.40–7.34) | 0.466 | 2.50 (0.57–11.00) | 0.226 | 1.76 (0.38–8.09) | 0.467 |
| Therapeutic scheme, Abi vs. Doc | 0.40 (0.19–0.84) | 0.015 | – | – | 0.33 (0.14–0.79) | 0.013 |
| ECOG score, ≥ 2 vs. < 2 | 1.60 (0.71–3.62) | 0.259 | 2.16 (0.92–5.04) | 0.076 | 2.00 (0.81–4.91) | 0.132 |
| ALP (IU/L), ≥ 160 vs < 160 | 2.97 (1.36–6.49) | 0.006 | 2.10 (0.81–5.42) | 0.125 | 2.82 (1.02–7.83) | 0.046 |
| LDH (IU/L), ≥ 250 vs < 250 | 3.20 (1.44–7.13) | 0.004 | 2.63 (1.02–6.79) | 0.046 | 1.68 (0.59–4.77) | 0.334 |
| C-index of the model | - | - | 0.719 | - | 0.778 | 0.009* |
| OS | Univariate analysis | Model without therapeutic scheme | Model with therapeutic scheme | |||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| CFS (mo), ≥ 10 vs. < 10 | 0.25 (0.09–0.66) | 0.005 | 0.15 (0.04–0.50) | 0.002 | 0.14 (0.04–0.46) | 0.001 |
| Gleason score, ≥ 8 vs. < 8 | 1.03 (0.24–4.45) | 0.969 | 1.50 (0.33–6.86) | 0.604 | 1.20 (0.25–5.79) | 0.819 |
| Therapeutic scheme, Abi vs. Doc | 0.48 (0.19–1.26) | 0.137 | – | – | 0.44 (0.14–1.37) | 0.157 |
| ECOG score, ≥ 2 vs. < 2 | 1.69 (0.64–4.42) | 0.288 | 2.65 (0.89–7.94) | 0.081 | 2.18 (0.71–6.73) | 0.174 |
| ALP (IU/L), ≥ 160 vs < 160 | 4.92 (1.84–13.17) | 0.002 | 2.13 (0.61–7.42) | 0.233 | 3.00 (0.73–12.26) | 0.127 |
| LDH (IU/L), ≥ 250 vs < 250 | 4.87 (1.79–13.26) | 0.002 | 3.37 (0.89–12.79) | 0.075 | 2.37 (0.55–10.34) | 0.250 |
| C-index of the model | - | - | 0.829 | 0.823 | 0.438* | |
*c-index test.
OS = overall survival from CRPC to death; HR = hazard ratio; CI = confidence interval; CFS = CRPC-free survival; IDC-P = intraductal carcinoma of the prostate; ECOG = Eastern Cooperative Oncology Group; Doc = docetaxel; Abi = abiraterone; ALP = alkaline phosphatase; LDH = lactate dehydrogenase.